The FDA Will Let One Licence Cover Patient-Specific Gene Edits, and CMS Is Taking Its Medicaid Gene Therapy Deals Beyond Sickle Cell
The FDA built the licence for bespoke gene editing. The Medicaid buying channel still covers one disease and two firms.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
The FDA Will Let One Licence Cover Patient-Specific Gene Edits, and CMS Is Taking Its Medicaid Gene Therapy Deals Beyond Sickle Cell
NICE Backed Arrowhead’s Plozasiran Eight Days After UK Authorisation, as a Cost Match for 57 to 114 People in England
Canada’s Drug Agency Has Drafted a Yes on Spinraza for Adults With SMA, Four Years After Telling Provinces Not to Pay
Enhertu Won EU Approval 39 Days After Its CHMP Opinion, and Payers Now Hold a Label Wider Than the Trial
China Approved Bayer’s Asundexian, the First Factor XIa Inhibitor, on a 26% Stroke Reduction, Three Years After It Lost to Apixaban
